Safety and efficacy of intravenousdiltiazem in atrial fibrillation or atrial flutter

Ellenbogen, Kenneth A.; Dias, Virgil C.; Cardello, Frank P.; Strauss, William; Simonton, Charles A.; Pollak, Scott J.; Wood, Mark A.; Stambler, Bruce S.

doi:10.1016/s0002-9149(99)80525-6

Cited by 68 publications

(30 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypotension was the most common side effect, occurring in 13 % of patients. Symptomatic hypotension was present in 3.6 % of patients, and responded to normal saline solution in all cases [291]. Similar beneficial actions were seen in another, placebo controlled study involving 113 AF or AFL patients without severe HF [292] as well as in 37 AF or AFL patients with moderate to severe congestive HF [293].…”

Section: Anipamil Animal Studies With Anipamilsupporting

confidence: 66%

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Szentandrássy

Nagy²,

Hegyi³

et al. 2014

CPD

View full text Add to dashboard Cite

Cardiac arrhythmias are a major cause of morbidity and mortality in the industrialized world. Among their treatment regimens one can find the calcium channel antagonists (CCAs), the class IV agents. In the cardiovascular system Land T-type calcium channels are found on vascular smooth muscle cells and cardiac myocytes with well defined physiological roles. Inhibition of calcium channels by CCAs has widely been used in clinical practice for several decades. Cardiovascular disorders are one of the many fields of medicine in which CCAs are used for various reasons and conditions. The three main indications of them are hypertension, angina and various cardiac arrhythmias. The most important classes of CCAs are dihydropyridines, phenylalkylamines and benzothiazepines but some newer compounds do not fall into any of these major classes. Dihydropyridines are not used in the antiarrhythmic therapy but are good vasodilators and antianginal agents. In contrast, phenylalkylamines and benzothiazepines exert cardiac actions in vivo and therefore these are one choice of antiarrhythmic drugs. This review focuses on phenylalkylamines, benzothiazepines and on new drugs with potential antiarrhythmic action in the heart as well as the mechanisms how calcium channels antagonism can lead to an antiarrhythmic action.

show abstract

Section: Anipamil Animal Studies With Anipamilsupporting

confidence: 66%

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Szentandrássy

Nagy²,

Hegyi³

et al. 2014

CPD

View full text Add to dashboard Cite

show abstract

“…IV diltiazem has been shown to slow ventricular rates in 94% of patients with AF within a median time of four minutes. 5 In this same study, there was a 13% incidence of hypotension, with 3.6% of patients requiring boluses of saline. In a separate study, IV diltiazem was shown to be effective in the treatment of AF in patients with moderate to severe CHF.…”

Section: Controlling Ventricular Ratementioning

confidence: 78%

Atrial Fibrillation: A Review of the Management in the Emergency Department

Best

1999

Ann Saudi Med

View full text Add to dashboard Cite

“…Both beta-blockers and calcium channel blockers are effective and well tolerated therapies for heart rate control in AF [26,27], and can be used in a wide range of clinical situations (acute and long-term) and in combination when single agent therapy is insufficient [18]. Both classes of agents have the added benefit of contributing to control of hypertension.…”

Section: The Case For Rate Controlmentioning

confidence: 99%

Pharmacologic approaches to rhythm versus rate control in atrial fibrillation—where are we now?

Wyse

2006

International Journal of Cardiology

View full text Add to dashboard Cite

Safety and efficacy of intravenousdiltiazem in atrial fibrillation or atrial flutter

Cited by 68 publications

References 14 publications

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy

Atrial Fibrillation: A Review of the Management in the Emergency Department

Pharmacologic approaches to rhythm versus rate control in atrial fibrillation—where are we now?

Contact Info

Product

Resources

About